Back to Search Start Over

LncRNA Gm43843 Promotes Cardiac Hypertrophy via miR-153-3p/Cacna1c Axis.

Authors :
Cai, Yuhua
Li, Yunpeng
Source :
Evidence-based Complementary & Alternative Medicine (eCAM). 10/10/2022, Vol. 2022, p1-13. 13p. 2 Color Photographs, 5 Graphs.
Publication Year :
2022

Abstract

Long noncoding RNAs (lncRNAs) have been reported to engage in many human diseases, including cardiac hypertrophy. Cardiac hypertrophy was mainly caused by excessive pressure load, which can eventually lead to a decline in myocardial contractility. Gm43843, a novel lncRNA, has not been well explored in cardiac hypertrophy so far. Herein, we are going to search the function and the underlying molecular mechanism of Gm43843 in cardiac hypertrophy. Gm43843 levels were measured via qRT-PCR in mouse myocardial cells when they are treated with angiogenin II (Ang II) or transfected with different plasmids. Western blot assay was implemented to detect the cardiac hypertrophy-related protein markers, while the cell was analyzed via immunofluorescence (IF) assay to evaluate the hypertrophy. Meanwhile, the binding of Gm43843 and the putative targets was examined based on mechanistic assay results. We found that Gm43843 expression was increased with the elevated concentration of Ang II. Inhibited Gm43843 was detected to reduce the hypertrophy of mouse myocardial cells. Meanwhile, Gm43843/miR-153-3p/Cacna1c axis was found to modulate cardiac hypertrophy. In short, Gm43843 promotes cardiac hypertrophy via miR-153-3p/Cacna1c axis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1741427X
Volume :
2022
Database :
Academic Search Index
Journal :
Evidence-based Complementary & Alternative Medicine (eCAM)
Publication Type :
Academic Journal
Accession number :
159720595
Full Text :
https://doi.org/10.1155/2022/2160804